Clinical Trial Update: A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

TAK-853 is being studied in adults with folate receptor alpha–positive advanced ovarian cancer and other solid tumors in Phase 1/Phase 2 trials; the study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• TAK-853

Snippet

Sponsor: Takeda | Conditions: Ovarian Cancer, Solid Tumors | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING